Tempus AI's growth story has become a real one, with Q2 revenue up 22% to $382.5 million, positive net income and EBITDA, a 73.5% gross margin and $816 million of cash. Its $1.5 billion Personalis deal owns the sequencing technology behind the Moderna-Merck mRNA cancer vaccine, whose strong Phase 3 melanoma results validated the bet. Piper Sandler upgraded it to Overweight with a $76 target, up from $56, citing Personalis and strong INTerpath-001 MRD data. $80 is support for the breakout. x.com 

Tempus AI's $1.5B all-stock acquisition of Personalis is smart long-term positioning despite the dilution-driven dip. Owning Personalis's NeXT Personal MRD technology outright lets Tempus pair liquid-biopsy recurrence testing, one of oncology's fastest-growing areas, with its multimodal dataset and AI at scale. That extends Tempus from diagnostics into high-margin longitudinal monitoring and could strengthen its moat, though execution will decide it. x.com 

Personalis no longer offers the hoped-for path to a Tempus stock swap, because its premium to the Tempus deal price makes a knockout cash offer the likelier outcome if the deal breaks. Tempus, Merck and other deal supporters own much of the equity, so a rival bid would need to be undeniably better and would probably be cash, nullifying the reason to hold even at a higher price. Biodesix looks more discounted, with 82% gross margins, 35% growth and a valuation below 3x revenue. x.com 

Personalis is rising because shareholders look increasingly likely to reject Tempus's takeover, not on hopes of a competing bid, so Craig-Hallum's downgrade misreads the move. Its Next platform will likely generate over $500 million of annual revenue, whatever Craig-Hallum says about the MRD market dwarfing Personalis's potential Moderna revenue. x.com 

Tempus AI's $1.5 billion all-stock acquisition of Personalis strengthens its position in precision oncology, adding Personalis' MRD platform, expanding its AI-driven diagnostics business and widening its opportunity in a market estimated at about $20 billion. The 6% drop on the news reflects dilution, timing ahead of earnings and near-term integration risk, a classic case of short-term dilution overshadowing long-term strategy. x.com  x.com 

Tempus AI's Personalis acquisition is a great strategic fit but raises the risk profile, because Tempus overpaid. Personalis adds longitudinal molecular-response and patient-outcome data that reinforce Tempus's data moat. But at roughly 19 times Personalis's guided 2026 revenue, with 15-20% gross margins and about $100M of cash burn, it adds burn on top of Tempus's own and could take years to become accretive. The thesis needs many years of patience and near-flawless execution. x.com  x.com 

Tempus AI has a fresh catalyst and a technical setup that could restart momentum. ARPA-H awarded up to $9.5M to build an autonomous clinical AI agent for heart failure, adding to an FDA clearance for an AI cardiovascular product, the Personalis deal and an AstraZeneca oncology foundation model. Q2 revenue rose 22%, oncology volume 31%, MRD tests reached 9,000, 2026 guidance rose to $1.6B and adjusted EBITDA turned positive. Price found support at the anchored VWAP from the lows. x.com  x.com 

Hims & Hers' compounding direct-to-consumer distribution makes it stupidly undervalued next to Tempus AI. Hims has $2.6B in trailing revenue at a $6.7B market cap, with 66.5% annual revenue growth from Q3 2021 to Q2 2026; Tempus has $1.4B in revenue, a $14.9B market cap and 40.4% annual growth. x.com 

Tempus AI is becoming a bigger health-tech player as pharma deals add a new services revenue stream beyond selling tests. BTIG's Mark Massaro raised his target to $80 from $70 with a Buy rating, mainly because Tempus will be the sequencing provider for Moderna and Merck's cancer vaccine program. The Personalis deal and MRD momentum add to a strengthening long-term AI and precision-oncology story, despite near-term volatility. x.com 

Tempus AI's latest news is good, even if that sounds crazy. x.com